Pfizer Stock Price, News & Analysis

AM Best has reaffirmed the Financial Strength Rating of A (Excellent) and Long-Term Issuer Credit Rating of 'a+' (Excellent) for Blue Whale Re Ltd., with a stable outlook. The ratings reflect Blue Whale's strong balance sheet and operating performance, underscoring its crucial role as the captive insurer for Pfizer (PFE). Despite its reliance on Pfizer for capitalization and reinsurance, Blue Whale's operations are expected to maintain strong results. However, any shifts in Pfizer's support could impact Blue Whale's ratings.

Pfizer Inc. (NYSE: PFE) has submitted a New Drug Application (NDA) to the FDA for PAXLOVID™, aimed at treating COVID-19 in high-risk patients. This follows data from the EPIC-HR study, which reported an 86% reduction in the risk of hospitalization or death. Notably, no deaths were recorded in PAXLOVID-treated patients through Week 24. The study highlights that 50-60% of the U.S. population carries risk factors for severe illness, reinforcing the drug's significance in combating COVID-19.

Pfizer and BioNTech have secured a new vaccine supply agreement with the U.S. government for 105 million doses of COVID-19 vaccines. The deal is worth $3.2 billion, with doses to be delivered by Q4 2022, potentially including Omicron-adapted vaccines pending FDA authorization. The agreement allows for an additional 195 million doses if required. This effort aims to ensure access to vaccines as COVID-19 variants evolve and will continue to provide free vaccinations to eligible U.S. residents.

Roivant Sciences and Pfizer have launched Priovant Therapeutics to focus on developing innovative therapies for autoimmune diseases. Priovant is advancing brepocitinib, a dual inhibitor of TYK2 and JAK1, showing statistically significant results in five Phase 2 studies. A Phase 3 trial for dermatomyositis (VALOR) has commenced, and top-line results from an ongoing Phase 2b study in systemic lupus erythematosus (SLE) are expected in the second half of 2023. Pfizer retains a 25% equity stake in Priovant and has licensed rights for both brepocitinib and ropsacitinib.

Pfizer and BioNTech announced positive results from their study of two Omicron-adapted COVID-19 vaccine candidates, a monovalent and a bivalent one. These candidates exhibited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg doses, respectively. The bivalent vaccine demonstrated a 9.1 and 10.9-fold increase against the same variant. Both candidates showed a favorable safety profile, and data will be discussed with regulatory authorities for potential emergency use authorization.

Pfizer Inc. (NYSE: PFE) is hosting a conference call on July 28, 2022, at 10 a.m. EDT to discuss its Second Quarter 2022 Performance Report. Investors and the public can access the event via webcast on Pfizer's investor website. To listen by phone, dial 800-456-4352 in the U.S. or 785-424-1086 internationally, using the password 'PFEQ222'. A transcript and replay will be available online within 24 hours after the call.

Pfizer continues its commitment to improving patient lives through innovative health care solutions.

Pfizer (NYSE: PFE) announced a $0.40 cash dividend for Q3 2022, marking the 335th consecutive quarterly dividend. This dividend will be payable on September 6, 2022, to shareholders on record as of July 29, 2022. Pfizer continues its commitment to return value to shareholders through consistent dividend payments.

Pfizer has announced a €90.5 million ($95 million) investment in Valneva, acquiring an 8.1% stake in the company. This investment is aimed at supporting the development of VLA15, a Lyme disease vaccine candidate, with the Phase 3 study set to begin in Q3 2022. Pfizer will also update the collaboration agreement with Valneva, increasing Valneva's contribution to 40% of shared development costs. The total potential milestone payments to Valneva remain at $168 million, with royalties adjusted to a tiered range of 14% to 22%.

Pfizer Inc. and BioNTech SE have received FDA emergency use authorization for their COVID-19 vaccine, now available for children aged 6 months to 4 years. The 3-µg dose showed a strong immune response and a favorable safety profile similar to the placebo in a Phase 2/3 clinical trial involving 4,526 children. The trial demonstrated immunogenicity comparable to older age groups, meeting regulatory non-inferiority criteria. The vaccine rollout is anticipated to begin following CDC recommendations, ensuring free access for U.S. residents.